To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

NCT04709328 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

690

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2

Interventions

DRUG: SCTA01
OTHER: Placebo

Sponsor

Sinocelltech Ltd.